Prof Roden, Germany explains why PPAR’s are interesting therapeutic targets not only to improve adipose tissue function but also for the liver. The approach can go beyond the improvement of liver function and aim at a more systemic approach with cardiovascular benefits.
Insulin resistance is tightly linked to NAFLD, particularly in those with Type 2 Diabetes. In this video, Prof. Michael Roden, Germany discusses this link, its origins that can inherited or acquired. He also sheds light on the consequences of insulin resistance.
NASH is associated with cardiovascular diseases and cardiovascular mortality. Prof Rosano, UK discusses the prevalence, risks and economic costs of NAFLD and NASH. He sheds lights on the risk of obesity that induces many changes. He also reviews countries with higher prevalence, age characteristics and the incidence and progression of the disease

The prevalence, risks and costs of NASH

, by

NASH is associated with cardiovascular diseases and cardiovascular mortality. Prof Rosano, UK discusses the prevalence, risks and economic costs of NAFLD and NASH. He sheds lights on the risk of obesity that induces many changes. He also reviews countries with higher prevalence, age characteristics and the incidence and progression of the disease

Prof Sacks, USA summarises what we know about the PPARs lipid effects. If the strongest evidence is with PPAR-alpha agonists for which the main lipid effect is lowering triglycerids, the are interesting information to discuss about PPAR-delta (Seladelpar).
Prof Bedossa discusses the definition of NAFLD / NASH and the role of liver biopsy. Liver biopsy cannot be used as a screening tool but is essential in clinical trials. To be useful, it has to be of a good quality and optimised. Prof Bedossa shares best practices in this regard.